More MS news articles for June 2002

LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12042813&dopt=Abstract

Nat Med 2002 Jun;8(6):613-9
Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA, Emery B, Turnley AM, Petratos S, Ernst M, Bartlett PF, Kilpatrick TJ.
The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Victoria, Australia.

Multiple sclerosis (MS) is a disabling inflammatory demyelinating disease of the central nervous system (CNS) that primarily affects young adults.

Available therapies can inhibit the inflammatory component of MS but do not suppress progressive clinical disability.

An alternative approach would be to inhibit mechanisms that drive the neuropathology of MS, which often includes the death of oligodendrocytes, the cells responsible for myelinating the CNS.

Identification of molecular mechanisms that mediate the stress response of oligodendrocytes to optimize their survival would serve this need.

This study shows that the neurotrophic cytokine leukemia inhibitory factor (LIF) directly prevents oligodendrocyte death in animal models of MS.

We also demonstrate that this therapeutic effect complements endogenous LIF receptor signaling, which already serves to limit oligodendrocyte loss during immune attack.

Our results provide a novel approach for the treatment of MS.